NextCell publishes its Year-End Report 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2021 –August 31, 2022 The report is available on the company’s website: 
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First NorthGrowth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Fourth quarter (2022-06-01 until 2022-08-31)

● Operating income amounted to 1 405 (1 381) TSEK.

● Operating result amounted to -8 563 (-4 457) TSEK.

● Earnings per share* amounted to -0,25 (-0,13) SEK.

● Cash and bank amounted to 97 117 (139 167) TSEK.

● Solidity** amounted to 92,7 (96,4) %.

Twelve months (2021-09-01 till 2022-08-31)

● Operating income amounted to 6 229 (4 455) TSEK.

● Operating result amounted to -34 554 (-24 557) TSEK.

● Earnings per share* amounted to -1,01 (-0,81) SEK.

● The Board of Directors proposes that no dividend is to be paid of the financial year.

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2021/2022: 34,379,523 (34,379,523) shares. Average number of shares for the full year 2021/2022: 34,379,523 (30,411,847) shares. Number of shares in NextCell as of August 31, 2022: 34,379,523 (34,379,523) shares.
**Solidity: Own capital's share of the sheet total

Significant events in the fourth quarter

● NextCell announced early June that all six children in the first part of the study had been treated with ProTrans. Patients would be monitored during the summer after which the safety of treatment would be evaluated by an independent Data Safety and Monitoring Board.

● NextCell announced in end of August that the Japan Patent Office (JPO) has issued a notice of allowance relating to the patent entitled "AllogeneicComposition" (publication number JP2020543858A). The patent describes the method of manufacturing the drug candidate ProTrans, where the selection algorithm is key for selecting optimal cells and donors. Patent protection is valid until 2039.

Significant events after thereporting period

● NextCell announced in late September that CEO Mathias Svahn would provide a status update at the Nordic Life Science days in Malmö.

● NextCell announced in mid-October that ProTrans cell therapy provides treatment effect 3.5years after treatment. Patients with type-1 diabetes undergoing two high-dose treatments of ProTrans cell therapy retain significantly higher endogenous insulin production than patients treated with low and medium dose.

● NextCell announced in mid-October that ProTrans cell therapy provides long-lasting therapeutic effect on type-1 diabetes after only one treatment. Patients treated 3 years ago with one dose of ProTrans in the placebo-controlled phase II study ProTrans-2 have maintained significantly higher endogenous insulin production than patients who received placebo, (63 percent vs. 23 percent). The 3-year results from the follow-up study (ProTrans-Obs) suggest that the treatment changes the course of the disease and that the effect persists over time.

● NextCell announced at the end of October thatthe Company's CEO, Mathias Svahn, will give a webcasted presentation of the latest published results.

This information isthe information that NextCell Pharma AB is required to disclose under the EUMarket Abuse Regulation. The information was provided by the below contactperson for publication on 27th October 2022, 07.30 CET.

‍

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Hemsida: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stem cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to a market approval for type-1 diabetes via a phase III study.  ProTrans is evaluated in two clinical Covid-19studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T  ‘and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍